StockData
Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc. (APUS) stock

APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$1.95−0.09 (-4.41%)

Close on Nov 17, 2026Market cap $2.94MP/E –Yield –

Apimeds Pharmaceuticals US r&d expenses

Research and development expenses are spending on new products and technology.

Apimeds Pharmaceuticals US's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.84M. For fiscal 2025 it was $1.63M, up 1556.7% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.63M+1556.7%
FY2023Dec 31, 2023$98.54K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$959.74K+47.2%
Q1 FY2026Mar 31, 2026$901.14K–
Q4 FY2025Dec 31, 2025$361.10K–
Q3 FY2025Sep 30, 2025$619.69K–
Q2 FY2025Jun 30, 2025$651.78K–

More Apimeds Pharmaceuticals US figures

See a number that looks wrong?